A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian

Phase 1b portion was completed; Phase 2 portion was not initiated.

Subjects must not have received prior weekly paclitaxel or more than 3 prior chemotherapy
regimens in the Phase 1b portion of the study and more than 2 prior chemotherapy regimens in
the Phase 2 portion of the study. Prior to enrollment, subjects will undergo screening to
determine study eligibility. In the Phase 1b portion of study, 3 subjects will be treated at
each dose level if no dose-limiting toxicities (DLTs) are observed. If 1 of 3 subjects
experiences a DLT, that dose level will be expanded to 6 subjects.

If 2 or more subjects experience a DLT, no further subjects will be dosed at that level and 3
additional subjects will be added to the preceding dose cohort unless 6 subjects have already
been treated at that dose level. Subjects will be assessed for DLTs from Days 0-28. Dose
escalation for newly enrolled subjects, if appropriate, will occur after all subjects in a
cohort have completed their Day 28 DLT assessment. After the final patient in the Phase 1b
portion of the trial has completed their Day 28 DLT assessment, 50 subjects will be enrolled
in the Phase 2 portion of the study and treated with demcizumab at the highest dose level
that had < 2 DLTs in the 6 subjects.

Inclusion Criteria:

1. Subjects must have cytologically or histologically confirmed ovarian, primary
peritoneal or fallopian tube cancer.. In addition, subjects must have a tumor that is
at least 1 cm in a single dimension and is radiographically apparent on CT, PET-CT or
MRI (i.e., RECIST version 1.1 measurable disease).

2. Subjects must have platinum resistant disease (i.e., which is defined as disease
progression in less than 6 months after receiving a minimum of 4 cycles of a platinum
containing regimen).

3. Subjects with the following histologic epithelial cell types are eligible: Serous
adenocarcinoma, endometrioid adenocarcinoma, mucinous adenocarcinoma, undifferentiated
carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, transitional cell
carcinoma, malignant Brenner's Tumor, or adenocarcinoma N.O.S.

4. Age >21 years

5. ECOG performance status <3

Exclusion Criteria:

1. Subjects receiving any other investigational medicinal product or anti-cancer therapy.

2. Prior therapy with weekly paclitaxel for recurrent disease (administration of weekly
paclitaxel as part of an upfront treatment strategy is acceptable as long as the
patient had not progressed while receiving weekly paclitaxel or recurred within 4
months of receiving weekly paclitaxel)

3. Non-epithelial ovarian carcinoma, including malignant mixed Mullerian tumors.

4. For the Phase 1b portion of the study, more than 3 prior chemotherapy regimens and for
the Phase 2 portion of the study more than 2 prior chemotherapy regimens. Maintenance
therapy following induction chemotherapy does not count as a separate regimen. In
addition, hormonal therapy (e.g., tamoxifen or an aromatase inhibitor) does not count
as a separate regimen.

5. Prior radiotherapy to the pelvis or abdomen

6. Subjects receiving heparin, warfarin, or other similar anticoagulants. Note: Subjects
may be receiving lowdose aspirin and/or non-steroidal anti-inflammatory agents.